Emerging treatment for advanced lung cancer with EGFR mutation. - Wikidata - awgldk - TriplyDB

Emerging treatment for advanced lung cancer with EGFR mutation.

Emerging treatment for advanced lung cancer with EGFR mutation.

http://www.wikidata.org/entity/Q34483953

about

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Kinases and cancer

P2860

Q33677872-48C056C2-6E5B-4B76-8017-FA214548A4D7 Q40610329-6CA79C12-37BA-473C-A24E-90B50FD75C10 Q54670763-9D33A621-DE69-4314-AAE4-8A087D55306D

P2860

Emerging treatment for advanced lung cancer with EGFR mutation.

http://www.wikidata.org/entity/Q34483953

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Emerging treatment for advanced lung cancer with EGFR mutation.

@ast

Emerging treatment for advanced lung cancer with EGFR mutation.

@en

Emerging treatment for advanced lung cancer with EGFR mutation.

@nl

type

label

Emerging treatment for advanced lung cancer with EGFR mutation.

@ast

Emerging treatment for advanced lung cancer with EGFR mutation.

@en

Emerging treatment for advanced lung cancer with EGFR mutation.

@nl

prefLabel

Emerging treatment for advanced lung cancer with EGFR mutation.

@ast

Emerging treatment for advanced lung cancer with EGFR mutation.

@en

Emerging treatment for advanced lung cancer with EGFR mutation.

@nl

P1433

Q34483953-EB6C819E-182D-4FBF-87B4-76808112BE39

P1476

Q34483953-74F1189D-A7B4-44FF-A4B5-6CCAF8DED614

P2093

Q34483953-200A6551-662E-43D5-A081-C7FCFC5127C2

Q34483953-2D545A81-0A6A-44F6-9E3F-672D4128DCDF

Q34483953-5305008A-1850-45B0-9549-292AFB751D0E

Q34483953-D5119DA0-C1EF-4409-9A46-2CEC9BE0C19C

Q34483953-EABF8EF5-BB4C-4BC0-8AC0-422C41AD1AF0

P2860

Q34483953-03933569-C758-4471-B63D-DCAB91B562FC

Q34483953-0AA411D9-986E-4613-B814-FCC35E92B72C

Q34483953-0F0BCF7D-2BA6-41C4-B4DF-16C60D1BB48D

Q34483953-0F42CB21-DC04-4497-B130-7408BDA849F8

Q34483953-1139905A-B0DF-4DB4-8908-A3AE53166AA8

Q34483953-1AA636A2-24EB-436F-9674-631E6779AF5B

Q34483953-21ABB876-0A8A-428B-A402-0C43BD75DB0D

Q34483953-247933D3-1F4F-4524-BE49-5DB8BADA3403

Q34483953-36A1E91A-A180-44E9-B1B0-AFD0A5713FC4

Q34483953-3FAB6670-32D8-4881-8297-A773F1C6A743

P304

Q34483953-CEB17511-EA4E-4BFB-9A47-37DF43D5B201

P31

Q34483953-9614ABC4-502D-4325-B3DF-C82F35BAF5B4

P356

Q34483953-A79D3B0B-D37D-42E5-A7BE-3AA39021FB84

P407

Q34483953-7F8B640C-7DA3-49C7-88C5-7BD6277EFB15

P433

Q34483953-52FD1A96-1761-45D0-9529-1378B44F5C1D

P478

Q34483953-DEEA39F6-0B06-4E0A-857D-3A2A70A3D5B2

P577

Q34483953-087F5B31-F2DC-41D2-B3CE-D586D7BA6C12

P698

Q34483953-1A3491AB-7C2A-42FF-B71F-486A3D013BCA

P356

14728214.2015.1058778

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging treatment for advanced lung cancer with EGFR mutation.

@en

P2093

Bilal Piperdi

http://www.w3.org/2001/XMLSchema#string

Cengiz Inal

http://www.w3.org/2001/XMLSchema#string

Emrullah Yilmaz

http://www.w3.org/2001/XMLSchema#string

Haiying Cheng

http://www.w3.org/2001/XMLSchema#string

Roman Perez-Soler

http://www.w3.org/2001/XMLSchema#string

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

597-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2015.1058778

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26153235

http://www.w3.org/2001/XMLSchema#string